Equity Profile

VKTX

Viking Therapeutics, Inc.

Health CareBiotechnology$3.8B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will provide insight into its financial health this quarter.

N/A

Revenue Growth

While specific revenue estimates are not available, revenue growth will be crucial to assess the company's market performance and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VKTX Q2-2026 Earnings Preview

Context

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is significant in the healthcare sector, particularly as the demand for effective treatments in these areas continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

In Q1-2026, Viking Therapeutics reported an EPS of -$1.37, which was significantly below the estimated -$0.95, leading to a stock decline of 3.27% the following day. The company has not provided specific guidance for the upcoming quarter.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are approaching Viking Therapeutics' upcoming earnings report with caution due to the company's recent earnings misses. The lack of analyst estimates adds uncertainty to market expectations.

Bull Case

If Viking can show improved EPS and demonstrate progress in its drug development pipeline, it could regain investor confidence and see a positive stock reaction.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, especially given the recent history of earnings misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

Given the recent history of earnings misses, the EPS figure will be crucial in determining market sentiment and stock movement.

What progress has been made in the drug development pipeline?

Updates on drug development could provide insights into future revenue potential and overall company growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Viking's potential for a turnaround based on recent pipeline developments that have not been fully communicated.

Supporting Evidence

The options market is pricing in a significant move of 26%, indicating that investors expect volatility that may not align with current sentiment.

Viking's recent drug trials have shown promising results that could lead to improved future earnings, contrary to the current bearish outlook.

Key Risk

If the EPS loss comes in better than expected, it could challenge the current negative sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing Viking's ability to turn around its financial performance and regain market trust.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would signal improved financial health and investor confidence.

Bear Confirmed If

An EPS loss greater than -$1.50 would reinforce concerns about the company's profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±26.04%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±26.0% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

44.1%

Calls (506K)P/C Ratio: 0.09Puts (79K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats expectations, history suggests the stock could react positively, potentially moving up by around 2.79% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average move of around 0.01% in such cases.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug development pipeline and timelines for potential product launches.
2Specific EPS figures and explanations for any changes compared to previous quarters.
3Management's outlook on revenue growth and market opportunities.
4Details on any partnerships or collaborations that could enhance product development.
5Responses to analyst questions regarding the company's strategy moving forward.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will provide insight into its financial health this quarter.

N/A

Revenue Growth

While specific revenue estimates are not available, revenue growth will be crucial to assess the company's market performance and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VKTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Viking can show improved EPS and demonstrate progress in its drug development pipeline, it could regain investor confidence and see a positive stock reaction.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, especially given the recent history of earnings misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

Given the recent history of earnings misses, the EPS figure will be crucial in determining market sentiment and stock movement.

What progress has been made in the drug development pipeline?

Updates on drug development could provide insights into future revenue potential and overall company growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Viking's potential for a turnaround based on recent pipeline developments that have not been fully communicated.

Supporting Evidence

The options market is pricing in a significant move of 26%, indicating that investors expect volatility that may not align with current sentiment.

Viking's recent drug trials have shown promising results that could lead to improved future earnings, contrary to the current bearish outlook.

Key Risk

If the EPS loss comes in better than expected, it could challenge the current negative sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing Viking's ability to turn around its financial performance and regain market trust.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would signal improved financial health and investor confidence.

Bear Confirmed If

An EPS loss greater than -$1.50 would reinforce concerns about the company's profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±26.04%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±26.0% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

44.1%

Calls (506K)P/C Ratio: 0.09Puts (79K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats expectations, history suggests the stock could react positively, potentially moving up by around 2.79% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average move of around 0.01% in such cases.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug development pipeline and timelines for potential product launches.
2Specific EPS figures and explanations for any changes compared to previous quarters.
3Management's outlook on revenue growth and market opportunities.
4Details on any partnerships or collaborations that could enhance product development.
5Responses to analyst questions regarding the company's strategy moving forward.